ENTPD1 and cancer: Adenosine-mediated immunosuppression is a major immune checkpoint for tumor-infiltrating CAR T cells, with the ectoenzymes CD73 and CD39, responsible for eADO production found to be overexpressed in multiple cancers and prognostic of poor patient outcomes27,29,65–67, and limiting both conventional chemo and immunotherapy treatments6,17.